Molecular Testing for Gastrointestinal Cancer

키워드

참고문헌 (131)

1. Bosman FT, "WHO classification of tumours of the digestive system", pp.13~177 (2010), IARC Press
2. Jemal A, "Global patterns of cancer incidence and mortality rates and trends", Cancer Epidemiol Biomarkers Prev, 19, pp.1893~1907 (2010)
3. 오창모, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013", Cancer Research and Treatment, 48(2), pp.436~450 (2016), 대한암학회
4. 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2016", Cancer Research and Treatment, 48(2), pp.451~457 (2016), 대한암학회
5. Boland CR, "A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition : development of international criteria for the determination of microsatellite instability in colorectal cancer", Cancer Res, 58, pp.5248~5257 (1998)
6. Douillard JY, "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer", N Engl J Med, 369, pp.1023~1034 (2013)
7. Lee HS, "Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma", Clin Cancer Res, 10, pp.1698~1705 (2004)
8. Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
9. Amin MB, "AJCC cancer staging manual", pp.203~274 (2017), Spinger
10. Jun SY, "Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma", Mod Pathol, 29, pp.402~415 (2016)
11. Peltomaki P, "Role of DNA mismatch repair defects in the pathogenesis of human cancer", J Clin Oncol, 21, pp.1174~1179 (2003)
12. Ionov Y, "Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis", Nature, 363, pp.558~561 (1993)
13. Boland CR, "Evolution of the nomenclature for the hereditary colorectal cancer syndromes", Fam Cancer, 4, pp.211~218 (2005)
14. Hampel H, "Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer", J Natl Compr Canc Netw, 8, pp.597~601 (2010)
15. Kloor M, "Analysis of EPCAM protein expression in diagnostics of Lynch syndrome", J Clin Oncol, 29, pp.223~227 (2011)
16. Huth C, "The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors", Mod Pathol, 25, pp.911~916 (2012)
17. Watson P, "The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome", Int J Cancer, 123, pp.444~449 (2008)
18. Kim JH, "Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers", Virchows Arch, 455, pp.485~494 (2009)
19. Thibodeau SN, "Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1", Cancer Res, 58, pp.1713~1718 (1998)
20. Edge SB, "AJCC cancer staging manual", pp.241~249 (2010), Springer
21. Sinicrope FA, "Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients", Gastroenterology, 131, pp.729~737 (2006)
22. 김주연, "Microsatellite Instability Status in Gastric Cancer: A Reappraisal of Its Clinical Significance and Relationship with Mucin Phenotypes", Journal of Pathology and Translational Medicine, 47(1), pp.28~35 (2013), 대한병리학회
23. Lee HS, "Distinct clinical features and outcomes of gastric cancers with microsatellite instability", Mod Pathol, 15, pp.632~640 (2002)
24. Choi YY, "Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis", J Surg Oncol, 110, pp.129~135 (2014)
25. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
26. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of human colon and rectal cancer", Nature, 487, pp.330~337 (2012)
27. Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)
28. Sargent DJ, "Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer", J Clin Oncol, 28, pp.3219~3226 (2010)
29. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
30. Rosenbaum MW, "PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes", Mod Pathol, 29, pp.1104~1112 (2016)
31. Xiao Y, "The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy", Cancer Discov, 5, pp.16~18 (2015)
32. Boger C, "PD-L1 is an independent prognostic predictor in gastric cancer of Western patients", Oncotarget, 7, pp.24269~24283 (2016)
33. Moreira L, "Identification of Lynch syndrome among patients with colorectal cancer", JAMA, 308, pp.1555~1565 (2012)
34. Buhard O, "Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis", Dis Markers, 20, pp.251~257 (2004)
35. Lindor NM, "Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors", J Clin Oncol, 20, pp.1043~1048 (2002)
36. de la Chapelle A, "Clinical relevance of microsatellite instability in colorectal cancer", J Clin Oncol, 28, pp.3380~3387 (2010)
37. Oh JR, "Microsatellite instability testing in Korean patients with colorectal cancer", Fam Cancer, 11, pp.459~466 (2012)
38. Lin EI, "Mutational profiling of colorectal cancers with microsatellite instability", Oncotarget, 6, pp.42334~42344 (2015)
39. Richman SD, "KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial", J Clin Oncol, 27, pp.5931~5937 (2009)
40. Phipps AI, "KRAS-mutation status in relation to colorectal cancer survival : the joint impact of correlated tumour markers", Br J Cancer, 108, pp.1757~1764 (2013)
41. Spano JP, "Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives", Ann Oncol, 16, pp.189~194 (2005)
42. Karapetis CS, "K-ras mutations and benefit from cetuximab in advanced colorectal cancer", N Engl J Med, 359, pp.1757~1765 (2008)
43. Van Cutsem E, "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", N Engl J Med, 360, pp.1408~1417 (2009)
44. Lievre A, "KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab", J Clin Oncol, 26, pp.374~379 (2008)
45. Smith G, "Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours : implications for personalised cancer medicine", Br J Cancer, 102, pp.693~703 (2010)
46. Vaughn CP, "Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer", Genes Chromosomes Cancer, 50, pp.307~312 (2011)
47. Heinemann V, "FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial", Lancet Oncol, 15, pp.1065~1075 (2014)
48. van Grieken NC, "KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study", Br J Cancer, 108, pp.1495~1501 (2013)
49. Lee SH, "BRAF and KRAS mutations in stomach cancer", Oncogene, 22, pp.6942~6945 (2003)
50. Bettington M, "The serrated pathway to colorectal carcinoma : current concepts and challenges", Histopathology, 62, pp.367~386 (2013)
51. Roth AD, "Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial", J Clin Oncol, 28, pp.466~474 (2010)
52. Sinicrope FA, "Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes", Gastroenterology, 148, pp.88~99 (2015)
53. Palomaki GE, "EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome", Genet Med, 11, pp.42~65 (2009)
54. De Roock W, "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis", Lancet Oncol, 11, pp.753~762 (2010)
55. Di Nicolantonio F, "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer", J Clin Oncol, 26, pp.5705~5712 (2008)
56. Kopetz S, "Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer", J Clin Oncol, 33, pp.4032~4038 (2015)
57. Corcoran RB, "Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer", J Clin Oncol, 33, pp.4023~4031 (2015)
58. Hyman DM, "Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations", N Engl J Med, 373, pp.726~736 (2015)
59. Perrone F, "PI3KCA", PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients, 2009, pp.20, 84~90
60. Nam SK, "BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis", PLoS One, 11, pp.e0151865~ (2016)
61. Prenen H, "PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer", Clin Cancer Res, 15, pp.3184~3188 (2009)
62. Janku F, "PIK3CA mutation H1047R is associated with response to PI3K", AKT, Cancer Res, pp.2013, 73[DOI]
63. Mei ZB, "Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis", Ann Oncol, 27, pp.1836~1848 (2016)
64. Liao X, "Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival", N Engl J Med, 367, pp.1596~1606 (2012)
65. Ogino S, "Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker : power and promise of molecular pathological epidemiology", Oncogene, 33, pp.2949~2955 (2014)
66. Franca LT, "A review of DNA sequencing techniques", Q Rev Biophys, 35, pp.169~200 (2002)
67. Ogino S, "Sensitive sequencing method for KRAS mutation detection by pyrosequencing", J Mol Diagn, 7, pp.413~421 (2005)
68. Ahmadian A, "Pyrosequencing: history, biochemistry and future", Clin Chim Acta, 363, pp.83~94 (2006)
69. Sundstrom M, "KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice", BMC Cancer, 10, pp.660~ (2010)
70. Altimari A, "454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalinfixed, paraffin-embedded samples", Onco Targets Ther, 6, pp.1057~1064 (2013)
71. Herreros-Villanueva M, "KRAS mutations: analytical considerations", Clin Chim Acta, 431, pp.211~220 (2014)
72. Kim MJ, "Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer", BMC Cancer, 12, pp.347~ (2012)
73. Miglio U, "Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay", Pathol Res Pract, 209, pp.233~236 (2013)
74. Gonzalez de Castro D, "A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens", Br J Cancer, 107, pp.345~351 (2012)
75. Oh JE, "Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes", J Mol Diagn, 12, pp.418~424 (2010)
76. Peeters M, "Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer", Clin Cancer Res, 19, pp.1902~1912 (2013)
77. Srinivasan M, "Effect of fixatives and tissue processing on the content and integrity of nucleic acids", Am J Pathol, 161, pp.1961~1971 (2002)
78. 이혜승, "Effects of Fixation and Storage of Human Tissue Samples on Nucleic Acid Preservation", Journal of Pathology and Translational Medicine, 48(1), pp.36~42 (2014), 대한병리학회[DOI]
79. Kamel-Reid S, "Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma", Arch Pathol Lab Med, 136, pp.26~32 (2012)
80. Yarden Y, "Untangling the ErbB signalling network", Nat Rev Mol Cell Biol, 2, pp.127~137 (2001)
81. Conradi LC, "Frequency of HER-2 positivity in rectal cancer and prognosis", Am J Surg Pathol, 37, pp.522~531 (2013)
82. Seo AN, "HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression", PLoS One, 9, pp.e98528~ (2014)
83. Sartore-Bianchi A, "Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12", 13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial, 2016, pp.17, 738~746
84. Schmoll HJ, "Targeting HER2: precision oncology for colorectal cancer", Lancet Oncol, 17, pp.685~686 (2016)
85. Ramanathan RK, "Low overexpression of HER-2", neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy: a phase II trial, 2004, pp.22, 858~865
86. Hurwitz H, "Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors", J Clin Oncol, 34(Suppl), pp.653~ (2016)
87. Bertotti A, "A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer", Cancer Discov, 1, pp.508~523 (2011)
88. Turner N, "Fibroblast growth factor signalling : from development to cancer", Nat Rev Cancer, 10, pp.116~129 (2010)
89. Dieci MV, "Fibroblast growth factor receptor inhibitors as a cancer treatment : from a biologic rationale to medical perspectives", Cancer Discov, 3, pp.264~279 (2013)
90. Bang YJ, "A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with fibroblast growth factor receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study", J Clin Oncol, 33(Suppl), pp.4014~ (2015)
91. Pearson A, "High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial", Cancer Discov, 6, pp.838~851 (2016)
92. Bardelli A, "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer", Cancer Discov, 3, pp.658~673 (2013)
93. Lee J, "Gastrointestinal malignancies harbor actionable MET exon 14 deletions", Oncotarget, 6, pp.28211~28222 (2015)
94. Pietrantonio F, "MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer", Cancer Discov, 6, pp.963~971 (2016)
95. Davies KD, "Molecular pathways : ROS1 fusion proteins in cancer", Clin Cancer Res, 19, pp.4040~4045 (2013)
96. Shaw AT, "Crizotinib in ROS1-rearranged non-small-cell lung cancer", N Engl J Med, 371, pp.1963~1971 (2014)
97. Lee J, "Identification of ROS1 rearrangement in gastric adenocarcinoma", Cancer, 119, pp.1627~1635 (2013)
98. Amatu A, "NTRK gene fusions as novel targets of cancer therapy across multiple tumour types", ESMO Open, 1, pp.e000023~ (2016)
99. Sartore-Bianchi A, "Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer", J Natl Cancer Inst, 108, pp.djv306~ (2016)
100. Kim KM, "Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force.", Asia Pac J Clin Oncol, 10, pp.297~307 (2014)
101. Fox SB, "Gastric HER2 Testing Study (GaTHER): an evaluation of gastric", gastroesophageal junction cancer testing accuracy in Australia, 2012, pp.36, 577~582
102. Ruschoff J, "HER2 testing in gastric cancer: a practical approach", Mod Pathol, 25, pp.637~650 (2012)
103. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
104. Lee HE, "Clinical significance of intratumoral HER2 heterogeneity in gastric cancer", Eur J Cancer, 49, pp.1448~1457 (2013)
105. Koudelakova V, "Evaluation of HER2 gene status in breast cancer samples with indeterminate fluorescence in situ hybridization by quantitative real-time PCR", J Mol Diagn, 17, pp.446~455 (2015)
106. Longnecker RM, "Fields virology", pp.1898~1959 (2013), Lippincott-Williams and Wilkins
107. Ma C, "Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability", Am J Surg Pathol, 40, pp.1496~1506 (2016)
108. Akihito Kawazoe, "Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients", Gastric Cancer, 20(3), pp.407~415 (2017), Springer Nature[DOI]
109. Chetty R, "Gastrointestinal cancers accompanied by a dense lymphoid component: an overview with special reference to gastric and colonic medullary and lymphoepithelioma-like carcinomas", J Clin Pathol, 65, pp.1062~1065 (2012)
110. Gulley ML, "Molecular diagnosis of Epstein-Barr virus-related diseases", J Mol Diagn, 3, pp.1~10 (2001)
111. Ambinder RF, "Epstein-Barr-encoded RNA in situ hybridization: diagnostic applications", Hum Pathol, 25, pp.602~605 (1994)
112. Carethers JM, "Genetics and genetic biomarkers in sporadic colorectal cancer", Gastroenterology, 149, pp.1177~1190.e3 (2015)
113. Chia NY, "Molecular classification of gastric cancer", Ann Oncol, 27, pp.763~769 (2016)
114. Chevrier S, "Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations", Int J Oncol, 45, pp.1167~1174 (2014)
115. Lin Y, "Gene mutations in gastric cancer: a review of recent next-generation sequencing studies", Tumour Biol, 36, pp.7385~7394 (2015)
116. Cerami E, "The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
117. Lee YS, "Genomic profile analysis of diffusetype gastric cancers", Genome Biol, 15, pp.R55~ (2014)
118. Li X, "Distinct subtypes of gastric cancer defined by molecular characterization include novel mutational signatures with prognostic capability", Cancer Res, 76, pp.1724~1732 (2016)
119. D’Haene N, "Clinical validation of targeted next generation sequencing for colon and lung cancers", PLoS One, 10, pp.e0138245~ (2015)
120. Mukherjee S, "Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors", Cancer Genet, 209, pp.119~129 (2016)
121. Yu J, "Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer", Gut, 64, pp.636~645 (2015)
122. Marrone M, "Multi-marker solid tumor panels using next-generation sequencing to direct molecularly targeted therapies", PLoS Curr, 6 (2014)
123. Wang K, "Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer", Nat Genet, 43, pp.1219~1223 (2011)
124. Wong SS, "Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing", Nat Commun, 5, pp.5477~ (2014)
125. Ali SM, "Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies", Oncologist, 20, pp.499~507 (2015)
126. Kuboki Y, "Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer", Ann Oncol, 27, pp.127~133 (2016)
127. Bria E, "Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis", Sci Rep, 6, pp.22982~ (2016)
128. Malapelle U, "Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases", J Clin Pathol, 69, pp.767~771 (2016)
129. Dallol A, "Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples", J Transl Med, 14, pp.118~ (2016)
130. Sakai K, "Extended RAS and BRAF mutation snalysis using next-generation sequencing", PLoS One, 10, pp.e0121891~ (2015)
131. Magliacane G, "Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics", Oncotarget, 6, pp.30592~30603 (2015)

관련 논문AI추천